TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36370892

Group type: EXPERIMENTAL
Intervention: Intervention aimed to increase comprehensive smokefree policies in the homes
Number of subjects: 191

Group type: COMPARATOR
Intervention: No ban on smoked tobacco products
Number of subjects: 191

Group type: COMPARATOR
Intervention: Partial or complete ban on smoked tobacco products
Number of subjects: 191

Group type: COMPARATOR
Intervention: Financial security perception
Number of subjects: 191
Study: 36370915

Group type: EXPERIMENTAL
Intervention: Ruminations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Future interventions
Number of subjects: 100
Study: 36371196

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with ARDS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher methylation of 'Apoptotic execution Pathway' genes (ROC1, ZNF789, H1F0) at inclusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of COVID-19 patients to controls at inclusion
Number of subjects: 100
Study: 36371222

Group type: EXPERIMENTAL
Intervention: Serum hemoglobin A1c level (per 1% increase)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Serum hemoglobin A1c level
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Optimal predictive cut-off value of hemoglobin A1c level for RPP
Number of subjects: 402
Study: 36371226

Group type: EXPERIMENTAL
Intervention: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly, 100 radioiodinated omburtamab injections at a recommended phase 2 dose of 1850 MBq/injection.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly.
Number of subjects: 38
Study: 36371330

Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Number of subjects: 15
Study: 36371408

Group type: EXPERIMENTAL
Intervention: 3.75 µg CoVLP+AS03
Number of subjects: 0
Study: 36371488

Group type: EXPERIMENTAL
Intervention: Spontaneous closure of iASD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Residual shunt group
Number of subjects: 36
Study: 36371986

Group type: EXPERIMENTAL
Intervention: Cold exposure for 120 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocking adipose triglyceride lipase (ATGL) with Atglistatin in mice
Number of subjects: 0
Study: 36372082

Group type: EXPERIMENTAL
Intervention: RSV-associated hospitalisations
Number of subjects: 9154

Group type: EXPERIMENTAL
Intervention: Paediatric intensive care unit admissions
Number of subjects: 9154

Group type: EXPERIMENTAL
Intervention: Active surveillance cohort for RSV infection
Number of subjects: 9154
Study: 36372245

Group type: EXPERIMENTAL
Intervention: AT-001 (1000 mg BID)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: AT-001 (1500 mg BID)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study: 36372251

Group type: EXPERIMENTAL
Intervention: Physical activity levels (measured by wrist-mounted triaxial accelerometer)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Healthy adults (age-matched NHANES participants)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Adults with chronic, stable HF (age-matched NHANES participants)
Number of subjects: 93
Study: 36372287

Group type: EXPERIMENTAL
Intervention: Non-hyperaemic Pd/Pa
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Hyperemic pressure ratio (FFR)
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Combined use of FFR and non-hyperaemic Pd/Pa
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Deferred revascularization in vessels with abnormal pressure ratios
Number of subjects: 2141
Study: 36372356

Group type: EXPERIMENTAL
Intervention: MSC infusion on the day of leukocyte recovery to 1000 cells/μL (engraftment, day E0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSC infusion on day E0
Number of subjects: 0
Study: 36372442

Group type: EXPERIMENTAL
Intervention: Temsavir (active moiety)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fostemsavir co-administration with hormone therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fostemsavir with combined oral contraceptives (COCs)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Other oestrogen-based therapies with fostemsavir
Number of subjects: 26
Study: 36372851

Group type: EXPERIMENTAL
Intervention: Cachexia (measured by bioelectrical impedance vector analysis)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 186

Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 186
Study: 36372873

Group type: EXPERIMENTAL
Intervention: CSF ctDNA positivity at baseline
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ≥ 50% reductions in CSF ctDNA concentrations after 8 weeks of treatment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ≥ 50% reductions in plasma ctDNA concentrations
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Clonal mutations remaining in more than 80% in CSF after 8 weeks
Number of subjects: 92
Study: 36372884

Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 20
Study: 36373234

Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP) in PCOS patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Androgen concentrations in PCOS patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sex-hormone-binding globulin in PCOS patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 66
Study: 36373249

Group type: EXPERIMENTAL
Intervention: Partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109) in combination with other antiviral agents
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109)
Number of subjects: 4
Study: 36373403

Group type: EXPERIMENTAL
Intervention: Total physical activity (PA)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Sports/exercise PA
Number of subjects: 321
Study: 36373555

Group type: EXPERIMENTAL
Intervention: Home exercise protocol for neck pain (4 weeks)
Number of subjects: 15
Study: 36373868

Group type: EXPERIMENTAL
Intervention: BurstDR™ spinal cord stimulation (SCS)
Number of subjects: 17
Study: 36374531

Group type: EXPERIMENTAL
Intervention: PRO mHealth tool intervention (6 PRO text messages a day for 12 months)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Completers (42 patients)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Noncompleters (19 patients)
Number of subjects: 61
Study: 36374541

Group type: EXPERIMENTAL
Intervention: Lifelight software
Number of subjects: 8585
Study: 36375046

Group type: EXPERIMENTAL
Intervention: LO-CHOP (lenalidomide and obinutuzumab with CHOP)
Number of subjects: 53
Study: 36375115

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Number of subjects: 139
Study: 36375120

Group type: EXPERIMENTAL
Intervention: NRX-0492
Number of subjects: 0
Study: 36375125

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Nonpalpable spleen
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 606
Study: 36375132

Group type: EXPERIMENTAL
Intervention: Carfilzomib (CFZ) combined with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE)
Number of subjects: 29
Study: 36375174

Group type: COMPARATOR
Intervention: Antipsychotics
Number of subjects: 2769

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 2769

Group type: COMPARATOR
Intervention: Mood stabilisers
Number of subjects: 2769
Study: 36375343

Group type: EXPERIMENTAL
Intervention: Narrative analysis of warning signs in the 24-h period prior to suicide attempt
Number of subjects: 35
Study: 36375653

Group type: EXPERIMENTAL
Intervention: N20Amp at 12-24 hours
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: N20Amp cutoff at 12-24 hours
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: N20Amp sensitivity at 12-24 hours
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: N20Amp decrease > 53%
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Combination of N20Amp decrease and N20Amp < 1.23 µV at 72 h
Number of subjects: 236
Study: 36375678

Group type: EXPERIMENTAL
Intervention: Venetoclax plus Obinutuzumab (VenO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil plus Obinutuzumab (ClbO)
Number of subjects: 0
Study: 36375835

Group type: EXPERIMENTAL
Intervention: Surpass Streamline flow diverter
Number of subjects: 180
Study: 36375971

Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antimicrobial therapy (OPAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of physician-side factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of OPAT patient cohort
Number of subjects: 0
Study: 36375981

Group type: EXPERIMENTAL
Intervention: FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin plus docetaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECF/ECX chemotherapy (epirubicin, cisplatin plus fluorouracil or capecitabine)
Number of subjects: 0
Study: 36375985

Group type: EXPERIMENTAL
Intervention: Uroflowmetry examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic dysfunction tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nerve conduction test
Number of subjects: 0
Study: 36376099

Group type: EXPERIMENTAL
Intervention: ClotPro® thromboelastometry analyser
Number of subjects: 321
Study: 36376109

Group type: EXPERIMENTAL
Intervention: Platelet function assessment on day 0, day 2, and day 7
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prophylactic anticoagulation
Number of subjects: 35
Study: 36376130

Group type: EXPERIMENTAL
Intervention: Oral administration of edaravone with a meal
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral administration of edaravone 8 hours after a high-fat meal
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral administration of edaravone 4 hours after a low-fat meal
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral administration of edaravone 2 hours after a light meal
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral administration of edaravone 1 hour before a high-fat meal
Number of subjects: 34
Study: 36376393

Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine at 10 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine at 25 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine at 50 μg
Number of subjects: 72
Study: 36376560

Group type: EXPERIMENTAL
Intervention: Pre-operative management
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intra-operative management
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Post-operative management
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Management of cases
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall management and cases
Number of subjects: 69
Study: 36376636

Group type: EXPERIMENTAL
Intervention: Lansoprazole (n=2656)
Number of subjects: 5311

Group type: EXPERIMENTAL
Intervention: Simvastatin (n=2655)
Number of subjects: 5311

Group type: EXPERIMENTAL
Intervention: Combination rationale (n=1786)
Number of subjects: 5311

Group type: EXPERIMENTAL
Intervention: Lack of benefit rationale (n=1755)
Number of subjects: 5311

Group type: EXPERIMENTAL
Intervention: Potential for harm rationale (n=1770)
Number of subjects: 5311
Study: 36376733

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 μg)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100 μg)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 μg and 100 μg)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study: 36376833

Group type: EXPERIMENTAL
Intervention: VEGF rs3025039 CC genotype
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: KDR rs2071559 AA genotype
Number of subjects: 200
Study: 36376960

Group type: EXPERIMENTAL
Intervention: Peer-supported intervention targeting diabetes and medication beliefs, communication, and self-efficacy skills; details on dosage and duration not specified.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Peer-supported intervention; details on dosage and duration not specified.
Number of subjects: 39
Study: 36377124

Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 413
Study: 36377504

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-652-3p
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-32-5p and miR-339-3p
Number of subjects: 0
Study: 36377523

Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment
Number of subjects: 180
Study: 36378074

Group type: EXPERIMENTAL
Intervention: BA.4/BA.5-adapted mRNA booster vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: BA.1-adapted mRNA vaccine (bivalent format: wild-type + BA.1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent wild-type + BA.4/BA.5 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent wild-type + Omicron BA.4/BA.5 vaccine
Number of subjects: 0
Study: 36378267

Group type: EXPERIMENTAL
Intervention: THC and CBD in edible cannabis products
Number of subjects: 0
Study: 36378539

Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 36378548

Group type: EXPERIMENTAL
Intervention: SRA737 (500 mg) combined with low-dose gemcitabine (250 mg/m2)
Number of subjects: 143
Study: 36378565

Group type: EXPERIMENTAL
Intervention: APACHE II
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: APACHE IV
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: SAPS-R
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: Overall model performance
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: Eleven models
Number of subjects: 3976
Study: 36378622

Group type: EXPERIMENTAL
Intervention: Time from biopsy to integrated histological-molecular diagnosis using whole-genome sequencing and epigenomic classification
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Process centred, patient centred and framework based measures
Number of subjects: 1000
Study: 36378673

Group type: EXPERIMENTAL
Intervention: SCAI stage B
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: SCAI stage C
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: SCAI stage D
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: SCAI stage E
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: SCAI classification at 24-h
Number of subjects: 237
Study: 36378678

Group type: EXPERIMENTAL
Intervention: PASCAL system (Edwards Lifesciences)
Number of subjects: 74
Study: 36378741

Group type: EXPERIMENTAL
Intervention: Lesion-specific IVUS-FFR ≤0.95
Number of subjects: 697

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 697
Study: 36378758

Group type: EXPERIMENTAL
Intervention: SES-disadvantage quintiles
Number of subjects: 593053
Study: 36378770

Group type: EXPERIMENTAL
Intervention: Decision Aids (DAs) for shared decision making (SDM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Implementation of DAs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CMS mandate for SDM
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clinician support for DAs
Number of subjects: 22
Study: 36378814

Group type: EXPERIMENTAL
Intervention: Helmet Pressure Support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal High-Flow
Number of subjects: 0
Study: 36378864

Group type: EXPERIMENTAL
Intervention: Bimatoprost Implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 36379002

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg intravenously once every 3 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 45
Study: 36379575

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) withdrawal after achieving inactive disease for 40 weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) retreatment for 12 weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (absence of MRI sacroiliitis and hs-CRP > 3 mg/L)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Male sex and age younger than 40 years
Number of subjects: 112
Study: 36379595

Group type: EXPERIMENTAL
Intervention: Delayed cytoreductive surgery (≥5 cycles of chemotherapy)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (after 3-4 cycles of chemotherapy)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No surgery (≥5 cycles of chemotherapy alone)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Facilitators/barriers to prevalent practice and access to cytoreductive surgery
Number of subjects: 1000
Study: 36379650

Group type: EXPERIMENTAL
Intervention: HPV vaccination knowledge, beliefs, and attitudes assessment through one-on-one interviews
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Use of mainstream media and top-down health education activities
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Engagement of local community health workers and established community social and leadership structures
Number of subjects: 45
Study: 36379649

Group type: EXPERIMENTAL
Intervention: Nurturing care and health determinants
Number of subjects: 5054

Group type: EXPERIMENTAL
Intervention: Geographical differences and disparities in healthcare
Number of subjects: 5054

Group type: EXPERIMENTAL
Intervention: Caregiving routines
Number of subjects: 5054
Study: 36379665

Group type: EXPERIMENTAL
Intervention: Concerns reported by parents, teachers, and nurses regarding children's well-being.
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Concerns regarding growth and/or physical symptoms.
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Concerns regarding emotions.
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Concerns regarding concentration.
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Overall concerns leading to school doctor actions.
Number of subjects: 1341
Study: 36379880

Group type: EXPERIMENTAL
Intervention: R-chemotherapy
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: G-chemotherapy
Number of subjects: 1202
Study: 36380152

Group type: EXPERIMENTAL
Intervention: RadioFrequency Ablation (RFA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 48
Study: 36380155

Group type: EXPERIMENTAL
Intervention: Image-guided Histotripsy
Number of subjects: 45
Study: 36380774

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 0
Study: 36381503

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine during ongoing siponimod treatment (cohort 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine during siponimod treatment interruption (cohort 2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine while on other DMTs or no therapy (cohort 3)
Number of subjects: 41
Study: 36381988

Group type: EXPERIMENTAL
Intervention: Speech-based artificial intelligence screening
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Speech-based screening in primary care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Speech-based amyloid pre-screening
Number of subjects: 200
Study: 36382108

Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg, orally administered, scaled by body weight)
Number of subjects: 22
Study: 36382109

Group type: EXPERIMENTAL
Intervention: Trotabresib 15, 30, and 45 mg combined with TMZ in the adjuvant setting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trotabresib 15 and 30 mg combined with TMZ+RT in the concomitant setting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trotabresib 30 mg established as the recommended phase II dose (RP2D) in both settings
Number of subjects: 32
Study: 36382118

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Gadolinium (Gd)+ lesions at baseline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Baseline EDSS ≥3.5
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Younger participants (<38 years at baseline)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Preexisting lesion counts > median (≥71 T2 hyperintense lesions)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Baseline T2 lesion volume
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Higher T2 volume
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Baseline EDSS <2
Number of subjects: 1008
Study: 36382130

Group type: EXPERIMENTAL
Intervention: Clazakizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 36382554

Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with ado-trastuzumab emtansine
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Placebo in combination with ado-trastuzumab emtansine
Number of subjects: 1700
Study: 36382599

Group type: EXPERIMENTAL
Intervention: Ticagrelor-based DAPT
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: De-escalation to clopidogrel after NB
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Nuisance bleeding (NB)
Number of subjects: 2583
Study: 36382911

Group type: EXPERIMENTAL
Intervention: Amino acid imaging with Carbon-11-Labeled Methionine PET/CT
Number of subjects: 7
Study: 36382956

Group type: EXPERIMENTAL
Intervention: Mean corCSA measured by noncontrast computed tomography
Number of subjects: 105
Study: 36383021

Group type: EXPERIMENTAL
Intervention: CoronaVac (inactivated vaccine)
Number of subjects: 148
Study: 36383213

Group type: EXPERIMENTAL
Intervention: Removal of amalgam restorations
Number of subjects: 0